Personal information

No personal information available

Activities

Works (43)

Data from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Data from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Data from Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Data from Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Tables 1-5 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Tables 1-5 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial

2024-09-16 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

2023-09-21 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

2023-09-21 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

2023-09-21 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

Clinical Cancer Research
2023-09-01 | Journal article
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Data from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-09-01 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-09-01 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-09-01 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-09-01 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-09-01 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-09-01 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-09-01 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Tables 1-5 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-09-01 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Tables 1-5 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-09-01 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Data from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-07-27 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-07-27 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-07-27 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-07-27 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-07-27 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-07-27 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-07-27 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Tables 1-5 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-07-27 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Tables 1-5 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

2023-07-27 | Preprint
Contributors: Terence M. Williams; Andreas Schneeweiss; Christian Jackisch; Changxian Shen; Karsten E. Weber; Peter A. Fasching; Carsten Denkert; Jenny Furlanetto; Ernst Heinmöller; Sabine Schmatloch et al.
Source: check_circle
Crossref

Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

2023-07-05 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

Clinical Cancer Research
2023-07-05 | Journal article
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

2023-07-05 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

2023-07-05 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

2023-05-16 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

2023-05-16 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref

Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

2023-05-16 | Preprint
Contributors: Peter A. Fasching; Christopher Szeto; Carsten Denkert; Stephen Benz; Karsten Weber; Patricia Spilman; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch et al.
Source: check_circle
Crossref